Researchers in Pennsylvania are pursuing a new approach to frontotemporal dementia, a fatal brain disease that most often strikes people in their 40s and 50s and currently has no treatment that slows its progression. A $446,875 grant from the National Institute on Aging is funding early-stage work on tiny RNA molecules designed to physically reverse the protein damage that kills neurons in a specific subtype of the disease.

Frontotemporal dementia is the most common form of dementia in people under 60, affecting an estimated 50,000 to 60,000 Americans. While Alzheimer's disease has seen several new drug approvals since 2023, FTD remains without any disease-modifying therapy. Patients typically survive 7 to 13 years after symptoms begin.

The Pennsylvania team is targeting a protein called TAF15, which in roughly 10% of FTD cases misfolds and clumps into toxic fibers inside neurons. A landmark 2023 study identified these TAF15 fibrils as the defining feature of this subtype, known as FTD-FET, elevating the protein from a scientific footnote to a serious drug target. The research now proposes short RNA molecules, each about 25 nucleotides long, that could prevent those clumps from forming and reverse ones that already exist, restoring the protein to its normal function inside the cell's nucleus.

The approach is distinct from most RNA-based drugs in development. Approved antisense oligonucleotide therapies, such as tofersen for a form of ALS, work by silencing faulty gene expression. These experimental RNAs would instead physically interact with misfolded proteins and unstick them, a mechanistic twist that has not yet been tested in patients but has shown early promise in lab settings.

The lab behind the grant has already demonstrated the technique works for two related proteins, TDP-43 and FUS, which drive ALS and other forms of FTD. In one key result, a short RNA penetrated neurons, reversed TDP-43 protein pathology, and slowed neurodegeneration in mice. The new work extends that platform to TAF15.

Pennsylvania has a particular stake in dementia research. About 19% of the state's population is 65 or older, above the national average, and institutions like the University of Pennsylvania host some of the country's leading FTD research and clinical programs. Penn consistently ranks among the top NIH-funded universities in the country, and Philadelphia's biotech corridor provides a pipeline for moving discoveries toward clinical use.

The grant is an R21 award, NIH's mechanism for high-risk, exploratory research, meaning it is designed to test whether the idea holds enough promise to justify larger investment. The two-phase plan will first identify which RNA sequences best prevent and reverse TAF15 aggregation in isolated protein systems, then test whether the strongest candidates protect human neurons in cell culture models of FTD-FET. If successful, the findings could support a future application for a larger clinical development grant.